1
|
Abstract
Extracorporeal membrane oxygenation (ECMO) has been advancing rapidly due to a combination of rising rates of acute and chronic lung diseases as well as significant improvements in the safety and efficacy of this therapeutic modality. However, the complexity of the ECMO blood circuit, and challenges with regard to clotting and bleeding, remain as barriers to further expansion of the technology. Recent advances in microfluidic fabrication techniques, devices, and systems present an opportunity to develop new solutions stemming from the ability to precisely maintain critical dimensions such as gas transfer membrane thickness and blood channel geometries, and to control levels of fluid shear within narrow ranges throughout the cartridge. Here, we present a physiologically inspired multilayer microfluidic oxygenator device that mimics physiologic blood flow patterns not only within individual layers but throughout a stacked device. Multiple layers of this microchannel device are integrated with a three-dimensional physiologically inspired distribution manifold that ensures smooth flow throughout the entire stacked device, including the critical entry and exit regions. We then demonstrate blood flows up to 200 ml/min in a multilayer device, with oxygen transfer rates capable of saturating venous blood, the highest of any microfluidic oxygenator, and a maximum blood flow rate of 480 ml/min in an eight-layer device, higher than any yet reported in a microfluidic device. Hemocompatibility and large animal studies utilizing these prototype devices are planned. Supplemental Visual Abstract, http://links.lww.com/ASAIO/A769.
Collapse
|
2
|
Astor TL, Borenstein JT. The microfluidic artificial lung: Mimicking nature's blood path design to solve the biocompatibility paradox. Artif Organs 2022; 46:1227-1239. [PMID: 35514275 DOI: 10.1111/aor.14266] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Revised: 04/03/2022] [Accepted: 04/04/2022] [Indexed: 11/28/2022]
Abstract
The increasing prevalence of chronic lung disease worldwide, combined with the emergence of multiple pandemics arising from respiratory viruses over the past century, highlights the need for safer and efficacious means for providing artificial lung support. Mechanical ventilation is currently used for the vast majority of patients suffering from acute and chronic lung failure, but risks further injury or infection to the patient's already compromised lung function. Extracorporeal membrane oxygenation (ECMO) has emerged as a means of providing direct gas exchange with the blood, but limited access to the technology and the complexity of the blood circuit have prevented the broader expansion of its use. A promising avenue toward simplifying and minimizing complications arising from the blood circuit, microfluidics-based artificial organ support, has emerged over the past decade as an opportunity to overcome many of the fundamental limitations of the current standard for ECMO cartridges, hollow fiber membrane oxygenators. The power of microfluidics technology for this application stems from its ability to recapitulate key aspects of physiological microcirculation, including the small dimensions of blood vessel structures and gas transfer membranes. An even greater advantage of microfluidics, the ability to configure blood flow patterns that mimic the smooth, branching nature of vascular networks, holds the potential to reduce the incidence of clotting and bleeding and to minimize reliance on anticoagulants. Here, we summarize recent progress and address future directions and goals for this potentially transformative approach to artificial lung support.
Collapse
Affiliation(s)
- Todd L Astor
- Biomembretics, Inc., Boston, Massachusetts, USA.,Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | | |
Collapse
|
3
|
Santos J, Vedula EM, Lai W, Isenberg BC, Lewis DJ, Lang D, Sutherland D, Roberts TR, Harea GT, Wells C, Teece B, Karandikar P, Urban J, Risoleo T, Gimbel A, Solt D, Leazer S, Chung KK, Sukavaneshvar S, Batchinsky AI, Borenstein JT. Toward Development of a Higher Flow Rate Hemocompatible Biomimetic Microfluidic Blood Oxygenator. MICROMACHINES 2021; 12:888. [PMID: 34442512 PMCID: PMC8398684 DOI: 10.3390/mi12080888] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Revised: 07/18/2021] [Accepted: 07/24/2021] [Indexed: 01/05/2023]
Abstract
The recent emergence of microfluidic extracorporeal lung support technologies presents an opportunity to achieve high gas transfer efficiency and improved hemocompatibility relative to the current standard of care in extracorporeal membrane oxygenation (ECMO). However, a critical challenge in the field is the ability to scale these devices to clinically relevant blood flow rates, in part because the typically very low blood flow in a single layer of a microfluidic oxygenator device requires stacking of a logistically challenging number of layers. We have developed biomimetic microfluidic oxygenators for the past decade and report here on the development of a high-flow (30 mL/min) single-layer prototype, scalable to larger structures via stacking and assembly with blood distribution manifolds. Microfluidic oxygenators were designed with biomimetic in-layer blood distribution manifolds and arrays of parallel transfer channels, and were fabricated using high precision machined durable metal master molds and microreplication with silicone films, resulting in large area gas transfer devices. Oxygen transfer was evaluated by flowing 100% O2 at 100 mL/min and blood at 0-30 mL/min while monitoring increases in O2 partial pressures in the blood. This design resulted in an oxygen saturation increase from 65% to 95% at 20 mL/min and operation up to 30 mL/min in multiple devices, the highest value yet recorded in a single layer microfluidic device. In addition to evaluation of the device for blood oxygenation, a 6-h in vitro hemocompatibility test was conducted on devices (n = 5) at a 25 mL/min blood flow rate with heparinized swine donor blood against control circuits (n = 3). Initial hemocompatibility results indicate that this technology has the potential to benefit future applications in extracorporeal lung support technologies for acute lung injury.
Collapse
Affiliation(s)
- Jose Santos
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Else M. Vedula
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Weixuan Lai
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Brett C. Isenberg
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Diana J. Lewis
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Dan Lang
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - David Sutherland
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Teryn R. Roberts
- Autonomous Reanimation and Evacuation (AREVA) Research Program, The Geneva Foundation, Brooks City Base, San Antonio, TX 78006, USA; (T.R.R.); (G.T.H.); (A.I.B.)
| | - George T. Harea
- Autonomous Reanimation and Evacuation (AREVA) Research Program, The Geneva Foundation, Brooks City Base, San Antonio, TX 78006, USA; (T.R.R.); (G.T.H.); (A.I.B.)
| | - Christian Wells
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Bryan Teece
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Paramesh Karandikar
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Joseph Urban
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Thomas Risoleo
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Alla Gimbel
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| | - Derek Solt
- Thrombodyne, Inc., Salt Lake City, UT 84103, USA; (D.S.); (S.S.)
| | - Sahar Leazer
- Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA; (S.L.); (K.K.C.)
| | - Kevin K. Chung
- Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA; (S.L.); (K.K.C.)
| | | | - Andriy I. Batchinsky
- Autonomous Reanimation and Evacuation (AREVA) Research Program, The Geneva Foundation, Brooks City Base, San Antonio, TX 78006, USA; (T.R.R.); (G.T.H.); (A.I.B.)
| | - Jeffrey T. Borenstein
- Draper, Cambridge, MA 02139, USA; (J.S.); (W.L.); (B.C.I.); (D.J.L.); (D.L.); (D.S.); (C.W.); (B.T.); (P.K.); (J.U.); (T.R.); (A.G.)
| |
Collapse
|
4
|
Gimbel AA, Hsiao JC, Kim ES, Lewis DJ, Risoleo TF, Urban JN, Borenstein JT. A high gas transfer efficiency microfluidic oxygenator for extracorporeal respiratory assist applications in critical care medicine. Artif Organs 2021; 45:E247-E264. [PMID: 33561881 DOI: 10.1111/aor.13935] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 01/10/2021] [Accepted: 02/05/2021] [Indexed: 12/15/2022]
Abstract
Advances in microfluidics technologies have spurred the development of a new generation of microfluidic respiratory assist devices, constructed using microfabrication techniques capable of producing microchannel dimensions similar to those found in human capillaries and gas transfer films in the same thickness range as the alveolar membrane. These devices have been tested in laboratory settings and in some cases in extracorporeal animal experiments, yet none have been advanced to human clinical studies. A major challenge in the development of microfluidic oxygenators is the difficulty in scaling the technology toward high blood flows necessary to support adult humans; such scaling efforts are often limited by the complexity of the fabrication process and the manner in which blood is distributed in a three-dimensional network of microchannels. Conceptually, a central advantage of microfluidic oxygenators over existing hollow-fiber membrane-based configurations is the potential for shallower channels and thinner gas transfer membranes, features that reduce oxygen diffusion distances, to result in a higher gas transfer efficiency defined as the ratio of the volume of oxygen transferred to the blood per unit time to the active surface area of the gas transfer membrane. If this ratio is not significantly higher than values reported for hollow fiber membrane oxygenators (HFMO), then the expected advantage of the microfluidic approach would not be realized in practice, potentially due to challenges encountered in blood distribution strategies when scaling microfluidic designs to higher flow rates. Here, we report on scaling of a microfluidic oxygenator design from 4 to 92 mL/min blood flow, within an order of magnitude of the flow rate required for neonatal applications. This scaled device is shown to have a gas transfer efficiency higher than any other reported system in the literature, including other microfluidic prototypes and commercial HFMO cartridges. While the high oxygen transfer efficiency is a promising advance toward clinical scaling of a microfluidic architecture, it is accompanied by an excessive blood pressure drop in the circuit, arising from a combination of shallow gas transfer channels and equally shallow distribution manifolds. Therefore, next-generation microfluidic oxygenators will require novel design and fabrication strategies to minimize pressure drops while maintaining very high oxygen transfer efficiencies.
Collapse
Affiliation(s)
| | | | - Ernest S Kim
- Bioengineering Division, Draper, Cambridge, MA, USA
| | | | | | | | | |
Collapse
|
5
|
Thompson AJ, Ma LJ, Major T, Jeakle M, Lautner-Csorba O, Goudie MJ, Handa H, Rojas-Peña A, Potkay JA. Assessing and improving the biocompatibility of microfluidic artificial lungs. Acta Biomater 2020; 112:190-201. [PMID: 32434076 PMCID: PMC10168296 DOI: 10.1016/j.actbio.2020.05.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 05/05/2020] [Accepted: 05/07/2020] [Indexed: 02/08/2023]
Abstract
Microfluidic artificial lungs (µALs) have the potential to improve the treatment and quality of life for patients with acute or chronic lung injury. In order to realize the full potential of this technology (including as a destination therapy), the biocompatibility of these devices needs to be improved to produce long-lasting devices that are safe for patient use with minimal or no systemic anticoagulation. Many studies exist which probe coagulation and thrombosis on polydimethyl siloxane (PDMS) surfaces, and many strategies have been explored to improve surface biocompatibility. As the field of µALs is young, there are few studies which investigate biocompatibility of functioning µALs; and even fewer which were performed in vivo. Here, we use both in vitro and in vivo models to investigate two strategies to improve µAL biocompatibility: 1) a hydrophilic surface coating (polyethylene glycol, PEG) to prevent surface fouling, and 2) the addition of nitric oxide (NO) to the sweep gas to inhibit platelet activation locally within the µAL. In this study, we challenge µALs with clottable blood or platelet-rich plasma (PRP) and monitor the resistance to blood flow over time. Device lifetime (the amount of time the µAL remains patent and unobstructed by clot) is used as the primary indicator of biocompatibility. This study is the first study to: 1) investigate the effect of NO release on biocompatibility in a microfluidic network; 2) combine a hydrophilic PEG coating with NO release to improve blood compatibility; and 3) perform extended in vivo biocompatibility testing of a µAL. We found that µALs challenged in vitro with PRP remained patent significantly longer when the sweep gas contained NO than without NO. In the in vivo rabbit model, neither approach alone (PEG coating nor NO sweep gas) significantly improved biocompatibility compared to controls (though with larger sample size significance may become apparent); while the combination of a PEG coating with NO sweep gas resulted in significant improvement of device lifetime. STATEMENT OF SIGNIFICANCE: The development of microfluidic artificial lungs (µALs) can potentially have a massive impact on the treatment of patients with acute and chronic lung impairments. Before these devices can be deployed clinically, the biocompatibility of µALs must be improved and more comprehensively understood. This work explores two strategies for improving biocompatibility, a hydrophilic surface coating (polyethylene glycol) for general surface passivation and the addition of nitric oxide (NO) to the sweep gas to quell platelet and leukocyte activation. These two strategies are investigated separately and as a combined device treatment. Devices are challenged with clottable blood using in vitro testing and in vivo testing in rabbits. This is the first study to our knowledge that allows statistical comparisons of biocompatible µALs in animals, a key step towards eventual clinical use.
Collapse
Affiliation(s)
- Alex J Thompson
- VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, USA, 48105; University of Michigan, 1150 W. Medical Center Drive, Ann Arbor, MI, USA, 48109.
| | - Lindsay J Ma
- VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, USA, 48105; University of Michigan, 1150 W. Medical Center Drive, Ann Arbor, MI, USA, 48109
| | - Terry Major
- University of Michigan, 1150 W. Medical Center Drive, Ann Arbor, MI, USA, 48109
| | - Mark Jeakle
- University of Michigan, 1150 W. Medical Center Drive, Ann Arbor, MI, USA, 48109
| | | | - Marcus J Goudie
- University of Georgia, College of Engineering, 220 Riverbend Road, Athens, GA, USA, 30602
| | - Hitesh Handa
- University of Georgia, College of Engineering, 220 Riverbend Road, Athens, GA, USA, 30602
| | - Alvaro Rojas-Peña
- University of Michigan, 1150 W. Medical Center Drive, Ann Arbor, MI, USA, 48109
| | - Joseph A Potkay
- VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, USA, 48105; University of Michigan, 1150 W. Medical Center Drive, Ann Arbor, MI, USA, 48109
| |
Collapse
|
6
|
Thompson AJ, Ma LJ, Plegue TJ, Potkay JA. Design Analysis and Optimization of a Single-Layer PDMS Microfluidic Artificial Lung. IEEE Trans Biomed Eng 2019; 66:1082-1093. [DOI: 10.1109/tbme.2018.2866782] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
7
|
Thompson AJ, Marks LH, Goudie MJ, Rojas-Pena A, Handa H, Potkay JA. A small-scale, rolled-membrane microfluidic artificial lung designed towards future large area manufacturing. BIOMICROFLUIDICS 2017; 11:024113. [PMID: 28798849 PMCID: PMC5533476 DOI: 10.1063/1.4979676] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Accepted: 03/22/2017] [Indexed: 05/22/2023]
Abstract
Artificial lungs have been used in the clinic for multiple decades to supplement patient pulmonary function. Recently, small-scale microfluidic artificial lungs (μAL) have been demonstrated with large surface area to blood volume ratios, biomimetic blood flow paths, and pressure drops compatible with pumpless operation. Initial small-scale microfluidic devices with blood flow rates in the μl/min to ml/min range have exhibited excellent gas transfer efficiencies; however, current manufacturing techniques may not be suitable for scaling up to human applications. Here, we present a new manufacturing technology for a microfluidic artificial lung in which the structure is assembled via a continuous "rolling" and bonding procedure from a single, patterned layer of polydimethyl siloxane (PDMS). This method is demonstrated in a small-scale four-layer device, but is expected to easily scale to larger area devices. The presented devices have a biomimetic branching blood flow network, 10 μm tall artificial capillaries, and a 66 μm thick gas transfer membrane. Gas transfer efficiency in blood was evaluated over a range of blood flow rates (0.1-1.25 ml/min) for two different sweep gases (pure O2, atmospheric air). The achieved gas transfer data closely follow predicted theoretical values for oxygenation and CO2 removal, while pressure drop is marginally higher than predicted. This work is the first step in developing a scalable method for creating large area microfluidic artificial lungs. Although designed for microfluidic artificial lungs, the presented technique is expected to result in the first manufacturing method capable of simply and easily creating large area microfluidic devices from PDMS.
Collapse
Affiliation(s)
| | - L H Marks
- VA Ann Arbor Healthcare System, Ann Arbor, Michigan 48105, USA
| | - M J Goudie
- College of Engineering, University of Georgia, Athens, Georgia 30602, USA
| | - A Rojas-Pena
- Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - H Handa
- College of Engineering, University of Georgia, Athens, Georgia 30602, USA
| | | |
Collapse
|
8
|
Gimbel AA, Flores E, Koo A, García-Cardeña G, Borenstein JT. Development of a biomimetic microfluidic oxygen transfer device. LAB ON A CHIP 2016; 16:3227-34. [PMID: 27411972 PMCID: PMC4987252 DOI: 10.1039/c6lc00641h] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Blood oxygenators provide crucial life support for patients suffering from respiratory failure, but their use is severely limited by the complex nature of the blood circuit and by complications including bleeding and clotting. We have fabricated and tested a multilayer microfluidic blood oxygenation prototype designed to have a lower blood prime volume and improved blood circulation relative to current hollow fiber cartridge oxygenators. Here we address processes for scaling the device toward clinically relevant oxygen transfer rates while maintaining a low prime volume of blood in the device, which is required for clinical applications in cardiopulmonary support and ultimately for chronic use. Approaches for scaling the device toward clinically relevant gas transfer rates, both by expanding the active surface area of the network of blood microchannels in a planar layer and by increasing the number of microfluidic layers stacked together in a three-dimensional device are addressed. In addition to reducing prime volume and enhancing gas transfer efficiency, the geometric properties of the microchannel networks are designed to increase device safety by providing a biomimetic and physiologically realistic flow path for the blood. Safety and hemocompatibility are also influenced by blood-surface interactions within the device. In order to further enhance device safety and hemocompatibility, we have demonstrated successful coating of the blood flow pathways with human endothelial cells, in order to confer the ability of the endothelium to inhibit coagulation and thrombus formation. Blood testing results provide confirmation of fibrin clot formation in non-endothelialized devices, while negligible clot formation was documented in cell-coated devices. Gas transfer testing demonstrates that the endothelial lining does not reduce the transfer efficiency relative to acellular devices. This process of scaling the microfluidic architecture and utilizing autologous cells to line the channels and mitigate coagulation represents a promising avenue for therapy for patients suffering from a range of acute and chronic lung diseases.
Collapse
Affiliation(s)
- A A Gimbel
- Department of Biomedical Engineering, The Charles Stark Draper Laboratory, Inc., Cambridge, MA 02139, USA.
| | - E Flores
- Department of Biomedical Engineering, The Charles Stark Draper Laboratory, Inc., Cambridge, MA 02139, USA.
| | - A Koo
- Laboratory for Systems Biology, Center for Excellence in Vascular Biology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
| | - G García-Cardeña
- Laboratory for Systems Biology, Center for Excellence in Vascular Biology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
| | - J T Borenstein
- Department of Biomedical Engineering, The Charles Stark Draper Laboratory, Inc., Cambridge, MA 02139, USA.
| |
Collapse
|